Heterotypic tumor spheroids: a platform for nanomedicine evaluation.
Co-culture spheroids
Endothelial
Fibroblast
Heterotypic spheroid
Immune cells
Nanomedicine
Tumor microenvironment
Journal
Journal of nanobiotechnology
ISSN: 1477-3155
Titre abrégé: J Nanobiotechnology
Pays: England
ID NLM: 101152208
Informations de publication
Date de publication:
02 Aug 2023
02 Aug 2023
Historique:
received:
09
03
2023
accepted:
23
07
2023
medline:
4
8
2023
pubmed:
3
8
2023
entrez:
2
8
2023
Statut:
epublish
Résumé
Nanomedicine has emerged as a promising therapeutic approach, but its translation to the clinic has been hindered by the lack of cellular models to anticipate how tumor cells will respond to therapy. Three-dimensional (3D) cell culture models are thought to more accurately recapitulate key features of primary tumors than two-dimensional (2D) cultures. Heterotypic 3D tumor spheroids, composed of multiple cell types, have become more popular than homotypic spheroids, which consist of a single cell type, as a superior model for mimicking in vivo tumor heterogeneity and physiology. The stromal interactions demonstrated in heterotypic 3D tumor spheroids can affect various aspects, including response to therapy, cancer progression, nanomedicine penetration, and drug resistance. Accordingly, to design more effective anticancer nanomedicinal therapeutics, not only tumor cells but also stromal cells (e.g., fibroblasts and immune cells) should be considered to create a more physiologically relevant in vivo microenvironment. This review aims to demonstrate current knowledge of heterotypic 3D tumor spheroids in cancer research, to illustrate current advances in utilizing these tumor models as a novel and versatile platform for in vitro evaluation of nanomedicine-based therapeutics in cancer research, and to discuss challenges, guidelines, and future directions in this field.
Identifiants
pubmed: 37533100
doi: 10.1186/s12951-023-02021-y
pii: 10.1186/s12951-023-02021-y
pmc: PMC10398970
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
249Informations de copyright
© 2023. The Author(s).
Références
J Control Release. 2022 Apr;344:62-79
pubmed: 35182612
J Control Release. 2018 Jan 28;270:246-259
pubmed: 29233763
Adv Healthc Mater. 2021 Oct;10(19):e2100794
pubmed: 34160137
Biotechnol Prog. 2021 Nov;37(6):e3203
pubmed: 34427389
Signal Transduct Target Ther. 2019 Aug 30;4:33
pubmed: 31637012
J Vis Exp. 2022 Apr 6;(182):
pubmed: 35467655
Cytotherapy. 2011 Sep;13(8):1000-12
pubmed: 21619419
J Biomed Sci. 2019 Oct 20;26(1):78
pubmed: 31629410
Acta Biomater. 2022 Mar 15;141:354-363
pubmed: 35007784
Br J Cancer. 2019 Jan;120(1):45-53
pubmed: 30413828
Nanomedicine. 2015 Nov;11(8):2013-23
pubmed: 26282381
Nat Rev Drug Discov. 2021 Feb;20(2):101-124
pubmed: 33277608
Oncotarget. 2017 May 2;8(18):30576-30586
pubmed: 28427165
Small. 2015 Feb 11;11(6):702-12
pubmed: 25331163
Biosens Bioelectron. 2022 Sep 15;212:114401
pubmed: 35617754
Nat Protoc. 2010 Nov;5(11):1844-56
pubmed: 21030959
Adv Drug Deliv Rev. 2021 Jun;173:306-330
pubmed: 33798642
Adv Healthc Mater. 2015 Aug 5;4(11):1664-74
pubmed: 26059746
Cancers (Basel). 2014 Aug 13;6(3):1670-90
pubmed: 25125485
ACS Omega. 2020 Feb 06;5(6):2939-2946
pubmed: 32095716
Biomed Mater. 2022 Feb 22;17(2):
pubmed: 35147520
Cancer Cell. 2006 May;9(5):391-403
pubmed: 16697959
Front Oncol. 2022 Apr 22;12:818437
pubmed: 35530312
Drug Discov Today. 2018 Apr;23(4):857-863
pubmed: 29428171
ACS Nano. 2016 Oct 25;10(10):9243-9258
pubmed: 27666558
Acta Pharm Sin B. 2023 May;13(5):1903-1918
pubmed: 37250157
Analyst. 2011 Feb 7;136(3):473-8
pubmed: 20967331
Nature. 2020 Jan;577(7789):254-259
pubmed: 31853059
Cancers (Basel). 2019 May 08;11(5):
pubmed: 31072019
Small. 2018 Oct;14(42):e1703617
pubmed: 30239130
Mol Med Rep. 2019 Jul;20(1):5-15
pubmed: 31115497
Drug Discov Today. 2020 May;25(5):879-890
pubmed: 32165322
Artif Cells Nanomed Biotechnol. 2019 Dec;47(1):123-131
pubmed: 30663429
J Control Release. 2020 Jul 10;323:398-411
pubmed: 32320816
APL Bioeng. 2023 Mar 28;7(1):016117
pubmed: 37006781
J Vis Exp. 2011 May 06;(51):
pubmed: 21587162
J Hematol Oncol. 2020 Jul 16;13(1):97
pubmed: 32677979
Int J Pharm. 2022 Apr 5;617:121585
pubmed: 35176332
ACS Appl Mater Interfaces. 2021 Mar 24;13(11):12824-12835
pubmed: 33689289
Int J Pharm. 2022 Apr 5;617:121577
pubmed: 35167901
Adv Biosyst. 2017 Oct;1(10):
pubmed: 30221187
Adv Exp Med Biol. 2021;1295:271-299
pubmed: 33543464
Biophys Rev Lett. 2020 Sep;15(3):131-141
pubmed: 33033500
Oncol Lett. 2017 Dec;14(6):6999-7010
pubmed: 29344128
J Biosci Bioeng. 2010 Nov;110(5):572-6
pubmed: 20591731
Anal Chem. 2010 May 15;82(10):3974-6
pubmed: 20426486
Biomaterials. 2020 Apr;238:119853
pubmed: 32062146
Front Bioeng Biotechnol. 2019 Aug 14;7:197
pubmed: 31475143
Mater Sci Eng C Mater Biol Appl. 2020 Nov;116:111229
pubmed: 32806313
J Clin Med. 2019 Oct 15;8(10):
pubmed: 31618880
Sci Rep. 2020 Feb 25;10(1):3362
pubmed: 32099027
Sci Rep. 2020 Dec 4;10(1):21273
pubmed: 33277538
Sci Rep. 2016 Jan 11;6:19103
pubmed: 26752500
Eur J Pharm Biopharm. 2019 Sep;142:195-203
pubmed: 31228557
Cell. 2020 Jan 9;180(1):188-204.e22
pubmed: 31883794
Biomaterials. 2019 Aug;213:119202
pubmed: 31132644
Sci Rep. 2018 Feb 5;8(1):2365
pubmed: 29403007
Front Bioeng Biotechnol. 2021 Dec 01;9:785937
pubmed: 34926430
Adv Exp Med Biol. 2021;1295:243-270
pubmed: 33543463
Pharmaceutics. 2021 Jun 17;13(6):
pubmed: 34204205
J Nanobiotechnology. 2021 Jan 6;19(1):3
pubmed: 33407564
Assay Drug Dev Technol. 2010 Oct;8(5):591-601
pubmed: 20658945
Mol Pharm. 2022 Jul 4;19(7):2549-2563
pubmed: 35583476
Int J Radiat Biol. 2007 Nov-Dec;83(11-12):849-71
pubmed: 18058370
Nat Nanotechnol. 2011 Oct 23;6(12):815-23
pubmed: 22020122
J Control Release. 2021 Mar 10;331:85-102
pubmed: 33388341
Sci Rep. 2018 Nov 21;8(1):17145
pubmed: 30464248
In Vitro Cell Dev Biol Anim. 2003 Jan-Feb;39(1-2):63-70
pubmed: 12892529
Life Sci. 2022 Mar 28;302:120505
pubmed: 35358594
Biomaterials. 2022 May;284:121469
pubmed: 35344799
J Exp Med. 2019 Mar 4;216(3):688-703
pubmed: 30710055
Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2010 May-Jun;2(3):219-31
pubmed: 20063369
Pharmaceutics. 2021 Jul 01;13(7):
pubmed: 34371697
Analyst. 2020 Oct 26;145(21):6937-6947
pubmed: 32851999
Cancers (Basel). 2019 Nov 08;11(11):
pubmed: 31717427
Int J Pharm. 2021 Sep 25;607:121044
pubmed: 34450227
ACS Biomater Sci Eng. 2022 Jul 11;8(7):3107-3121
pubmed: 35678715
Front Biosci (Landmark Ed). 2010 Jan 01;15(1):166-79
pubmed: 20036813
Pharmaceutics. 2020 Dec 06;12(12):
pubmed: 33291351
Nanomedicine. 2020 Aug;28:102183
pubmed: 32222478
Pharmaceutics. 2021 Nov 08;13(11):
pubmed: 34834307
Biofabrication. 2022 Oct 28;15(1):
pubmed: 36126647
J Exp Clin Cancer Res. 2018 Jan 12;37(1):4
pubmed: 29329547
Adv Pharm Bull. 2020 Sep;10(4):556-565
pubmed: 33062602
Adv Mater. 2022 Apr;34(13):e2107964
pubmed: 35100658
Polymers (Basel). 2022 Sep 08;14(18):
pubmed: 36145898
Biomed Mater. 2017 Mar 15;12(2):025009
pubmed: 28143999
Lab Chip. 2015 Feb 21;15(4):1072-83
pubmed: 25519528
PLoS One. 2016 Jul 08;11(7):e0159013
pubmed: 27391808
J Mater Chem B. 2021 Nov 17;9(44):9123-9135
pubmed: 34676865
J Control Release. 2012 Dec 10;164(2):192-204
pubmed: 22613880
Acta Biomater. 2020 Jul 15;111:349-362
pubmed: 32413579
BMC Cancer. 2020 May 27;20(1):475
pubmed: 32460715
Analyst. 2022 May 17;147(10):2023-2034
pubmed: 35485712
Int J Cancer. 2002 Nov 10;102(2):129-36
pubmed: 12385007
Drug Metab Pharmacokinet. 2022 Dec;47:100469
pubmed: 36174354
Front Bioeng Biotechnol. 2016 Feb 12;4:12
pubmed: 26904541
Lab Chip. 2007 Jun;7(6):770-6
pubmed: 17538720
Theranostics. 2012;2(1):66-75
pubmed: 22272220
J Control Release. 2015 Oct 10;215:39-54
pubmed: 26220617
Chem Sci. 2021 Jan 28;12(11):4021-4027
pubmed: 34163672
J Control Release. 2016 Dec 28;244(Pt B):257-268
pubmed: 27616660
Micromachines (Basel). 2018 Feb 25;9(3):
pubmed: 30424028
J Control Release. 2020 May 10;321:564-575
pubmed: 32112854
Int J Biol Macromol. 2022 Oct 1;218:384-393
pubmed: 35902009
J Appl Toxicol. 2022 Jan;42(1):52-72
pubmed: 34060108
Transl Oncol. 2019 Jan;12(1):180-189
pubmed: 30554606
Nanoscale. 2016 Oct 06;8(39):17322-17332
pubmed: 27714104
Part Fibre Toxicol. 2019 Jun 3;16(1):22
pubmed: 31159811
Biomater Sci. 2021 Aug 21;9(16):5407-5414
pubmed: 34318804
Sci Rep. 2019 May 8;9(1):7103
pubmed: 31068603
Biomicrofluidics. 2013 Oct 08;7(5):54114
pubmed: 24396525
Pharmaceutics. 2022 Jan 03;14(1):
pubmed: 35057002
Nanoscale Horiz. 2020 Mar 1;5(3):400-430
pubmed: 32118219
J Tissue Eng. 2017 Jun 30;8:2041731417718391
pubmed: 35003617
Molecules. 2020 May 08;25(9):
pubmed: 32397080
Exp Cell Res. 2001 May 15;266(1):74-86
pubmed: 11339826
Acta Biomater. 2019 Aug;94:392-409
pubmed: 31200118
Proc Natl Acad Sci U S A. 2015 Oct 27;112(43):13308-11
pubmed: 26460009
Front Cell Dev Biol. 2021 Sep 23;9:696668
pubmed: 34631696
Molecules. 2018 Dec 18;23(12):
pubmed: 30567363
Sci Rep. 2020 Dec 17;10(1):22171
pubmed: 33335148
Int J Pharm. 2022 Sep 25;625:122076
pubmed: 35931394
J Control Release. 2022 Sep;349:731-743
pubmed: 35905784
Cancers (Basel). 2022 Feb 15;14(4):
pubmed: 35205707
Cancer Cell Int. 2021 Mar 4;21(1):152
pubmed: 33663530